Effects of increasing the PSA cutoff to perform additional biomarker tests before prostate biopsy

BACKGROUND: Multi-step testing might enhance performance of the prostate cancer diagnostic pipeline. Using PSA >1 ng/ml for first-line risk stratification and the Stockholm 3 Model (S3M) blood-test >10% risk of Gleason Score > 7 prostate cancer to inform biopsy decisions has been suggested....

Descripción completa

Detalles Bibliográficos
Autores principales: Nordström, Tobias, Adolfsson, Jan, Grönberg, Henrik, Eklund, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627473/
https://www.ncbi.nlm.nih.gov/pubmed/28974201
http://dx.doi.org/10.1186/s12894-017-0281-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627473/
https://www.ncbi.nlm.nih.gov/pubmed/28974201
http://dx.doi.org/10.1186/s12894-017-0281-8

Ejemplares similares